Zeta CD 15 Antibody. Zeta’s mouse monoclonal antibody recognizes CD15 (also known as 3-fucosyl-N-acetyllactosamine or 3-FAL), which plays a role in mediating phagocytosis, bactericidal activity, and chemotaxis. CD15 is present on >95% of granulocytes including neutrophils and eosinophils and to a lesser degree on monocytes. CD15 is also expressed in Reed-Sternberg cells and some epithelial cells. CD15 antibody is very useful in the identification of Hodgkin’s disease. CD15 is occasionally expressed in large cell lymphomas of both B and T phenotypes which otherwise have a quite distinct histological appearance.
CD15 cam be used as marker for Hodgkin’s lymphoma but also is a poor prognostic marker in acute promyelocytic leukemia and can differentiate pulmonary adenocarcinoma (CD15+) from mesothelioma (CD15-).
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.